Evidence map›Paper›PMID 41799800›Full record

ArticlebioRxiv : the preprint server for biology2026

Computational discovery of precision therapeutics for hidradenitis suppurativa.

Ernest Y Lee, Phoebe Leboit, Haley B Naik, Alice S Tang, Francesco Vallania, Ashley E Yates, Daniel M Klufas, Scott L Hansen, Michael D Rosenblum, Margaret M Lowe and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ernest Y LeeDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-5144-2552
Phoebe LeboitDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Haley B NaikDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Alice S TangDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA, United States.
Francesco VallaniaimmunoLogic, San Francisco, CA, United States.
Ashley E YatesDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Daniel M KlufasDepartment of Dermatology, University of Connecticut, Farmington, CT, United States.
Scott L HansenDepartment of Surgery, UCSF, San Francisco, California, United States.
Michael D RosenblumDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Margaret M LoweDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Marina SirotaDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA, United States.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
UCSF Dermatology Training GrantT32AR007175 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Wilson Liao, Michael David Rosenblum · 1986 to 2026
$6.1M
Restoring Immune Balance in Hiddradenitis SuppurativaR01AR075864 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENBLUM, MICHAEL DAVID · 2020 to 2024
$3.5M
Elucidating the Cellular and Molecular Mechanisms of How Regulatory T cells in Skin Regulate Fibroblast Activation and Tissue FibrosisR01AR071944 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENBLUM, MICHAEL DAVID · 2018 to 2022
$1.7M
Leveraging Clinical Data for Phenotyping and Predictive Modelling of Alzheimer’s DiseaseF30AG079504 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TANG, ALICE SUMMER · 2022 to 2025
$187k
NIAMS NIH HHS P30 AR070155NIAMS NIH HHS R01 AR071944NIAMS NIH HHS R01 AR075864NIAMS NIH HHS T32 AR007175NIA NIH HHS F30 AG079504NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM007618
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is an underdiagnosed chronic, immune-mediated inflammatory skin disease that causes severe pain, drainage, and scarring, leading to significant physical and psychosocial burdens. HS is characterized by heterogenous molecular changes that are poorly understood, posing a significant challenge for drug development. Therapeutic options remain limited, and many patients experience disease relapse despite treatment. Therefore, precision medicine approaches are urgently needed to identify new therapies for HS. Here, we combine integrative transcriptomics, large-scale drug perturbational datasets, and translational immunology to identify sirolimus, pioglitazone, and fulvestrant as novel therapies for HS that can directly target and reverse the HS disease gene signature in immune cell types relevant to HS pathogenesis. Using a novel

Identifiers

PMID41799800
PMCPMC12964703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.